Does pravastatin reduce lung metastasis of rat hepatocellular carcinoma via a coordinated decrease of MMP expression and activity?
Pravastatin reduces progression and limits metastatic diffusion of established HCC. This could be linked to the decreased MMP activity. These results, obtained in a very aggressive HCC model, further suggest the potential benefit of statins in human HCC.
Despite adequate patient information and compliance the rate of nephrolithiasis during indinavir therapy was 12.4%.